Skip to main navigation Skip to main content
info(at)avldigital.remove-this.de
Deutsch English
Narrow Search
Search narrowed by
Last searches

Results for *

Displaying results 1 to 5 of 5.

  1. Expanding and improving Medicare
    prescription drugs, an Oregon perspective ; field hearing before the Special Committee on Aging, United States Senate, One Hundred Seventh Congress, second session, Beaverton, OR, August 15, 2002
    Published: 2002
    Publisher:  US Gov. Print. Off., Washington, DC

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    B 335996
    Inter-library loan:
    Unlimited inter-library loan, copies and loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Subjects: Gesetzliche Krankenversicherung; Arzneimittelmarkt; Arzneimittel; Ältere Menschen; USA; Medicare; Older people; Prescription pricing; Insurance, Pharmaceutical services
    Scope: III, 47 S, 24 cm
  2. Medicare payments for currently covered prescription drugs
    hearing before the Subcommittee on Health of the Committee on Ways and Means, House of Representatives, One Hundred Seventh Congress, second session, October 3, 2002
    Published: 2003

    Location:
    Universitätsbibliothek Braunschweig
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    C 241150
    Inter-library loan:
    No inter-library loan
    Export to reference management software   RIS file
      BibTeX file
    Content information
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Edition: [Elektronische Ressource]
    Subjects: Gesetzliche Krankenversicherung; Arzneimittel; USA; Versicherungsschutz; Medicare; Insurance, Pharmaceutical services; Prescription pricing; Drugs
    Scope: Online-Ressource, III, 89 p., text
    Notes:

    Includes bibliographical references
  3. Designing a twenty-first century Medicare prescription drug benefit
    hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighth Congress, first session, April 8, 2003
    Published: 2003

    Location:
    Universitätsbibliothek Braunschweig
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    C 244998
    Inter-library loan:
    No inter-library loan
    Export to reference management software   RIS file
      BibTeX file
    Content information
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Subjects: Arzneimittel; Gesetzliche Krankenversicherung; Sozialleistungsempfänger; Gesundheitskosten; Gesundheitspolitik; USA; Medicare; Older people; Insurance, Pharmaceutical services; Drugs
    Scope: Online-Ressource, III, 76 p., text, ill
    Notes:

    Includes bibliographical references
  4. Managed care, drug benefits and mortality
    an analysis of the elderly
    Author: Gowrisankaran, Gautam; Town, Robert J.
    Published: 2004
    Publisher:  National Bureau of Economic Research, Cambridge, Mass.

    "We seek to investigate whether managed health care can affect mortality, and if so, through which mechanisms. We estimate the impact of Medicare+Choice (M+C), Medicare's managed care program, on elderly mortality, using a county-level panel from... more

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (10204)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan

     

    "We seek to investigate whether managed health care can affect mortality, and if so, through which mechanisms. We estimate the impact of Medicare+Choice (M+C), Medicare's managed care program, on elderly mortality, using a county-level panel from 1993 to 2000. We control for endogenous M+C penetration rates with county fixed effects and instrumental variables. We construct instruments using the identification created by the fact that M+C payment rates are based on 3 to 8 year lagged fee-for-service (FFS) costs in the county. We find that enrollment in managed care without prescription drug coverage significantly increases mortality while enrollment in managed care with drug coverage has no significant impact, both relative to FFS. The impact of managed care penetration on mortality from heart disease appears to follow a similar pattern. The estimates suggest that a 10-percentage point increase in M+C non-drug coverage would cause 51,000 additional deaths among the aged population in 2000"--National Bureau of Economic Research web site

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: NBER working paper series ; 10204
    Subjects: Integrierte Versorgung; Arzneimittel; Gesetzliche Krankenversicherung; Sozialleistungsempfänger; Sterblichkeit; Schätzung; USA; Managed care plans (Medical care); Mortality; Drugs; Insurance, Pharmaceutical services; Older people
    Scope: 35 S
    Notes:

    Literaturverz. S.27-29

    Internetausg.: papers.nber.org/papers/w10204.pdf - lizenzpflichtig
  5. Does cost sharing affect compliance?
    The case of prescription drugs
    Author: Dor, Avi; Encinosa, William E.
    Published: 2004
    Publisher:  National Bureau of Economic Research, Cambridge, Mass.

    "Private insurance for prescription drugs is characterized by two regimes: flat copayments and variable co-insurance. We develop a simple model to show that patient compliance is lower under coinsurance due to uncertainty in cost-sharing. ... more

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (10738)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan

    Location:
    ifo Institut für Wirtschaftsforschung an der Universität München, Bibliothek
    Signature:
    82/766 B-10738
    Inter-library loan:
    No inter-library loan

     

    "Private insurance for prescription drugs is characterized by two regimes: flat copayments and variable co-insurance. We develop a simple model to show that patient compliance is lower under coinsurance due to uncertainty in cost-sharing. Empirically, we derive comparable models for compliance behavior in the two regimes. Using claims data from nine large firms, we focus our analysis on diabetes, a common chronic condition that leads to severe complications when inappropriately treated. In the coinsurance model, an increase in the coinsurance rate from 20% to 75% resulted in the share of persons who never comply to increase by 9.9%, and reduced the share of fully compliant persons by 24.6%. In the copayment model, an increase in the copayment from $6 to $10 resulted in a 6.2% increase in the share of never-compliers, and a concomitant 9% reduction in the share of full compliers. Similar results hold when the level of cost-sharing is held constant across regimes. While non-compliance reduces expenditures on prescription drugs it may also lead to increases in indirect medical costs due to avertable complications. Using available aggregate estimates of the cost of diabetic complications, we calculate that the $6-$10 increase in copayment would have the direct effect of reducing national drug spending for diabetes by $125 million. However, the increase in non-compliance rates is expected to increase the rate of diabetic complications resulting in an additional $360 million in treatment costs. The results suggest that both private payers and public payers may be able to reduce overall medical costs by switching from coinsurance to copayments in prescription drug plans"--National Bureau of Economic Research web site

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: NBER working paper series ; 10738
    Subjects: Private Krankenversicherung; Arzneimittel; Diabetes; Schätzung; USA; Drugs; Prescription pricing; Insurance, Pharmaceutical services
    Scope: 28, [2] S, graph. Darst
    Notes:

    Internetausg.: papers.nber.org/papers/w10738.pdf - lizenzpflichtig